Wegovy and Ozempic belong to the class of drugs called glucagon-like peptide-1 receptor agonists (GLP-1s). Both are manufactured by Novo Nordisk and contain semaglutide as their active ingredient.
Semaglutide was first sold under Ozempic in 2017 when it was developed as a diabetes medication. Wegovy, which includes a higher dose of semaglutide, was introduced by the manufacturer in 2021.
Ozempic was initially intended to treat type 2 diabetes, while Wegovy contains a higher dose of semaglutide and was specifically developed to treat overweight and obesity. When used along with behavioural modifications like diet and exercise, Wegovy and Ozempic are approved for chronic weight management.
These medications are approved for people with a body mass index (BMI) of 30 or higher or for people with a BMI of 27 or greater and with a metabolic condition, like type 2 diabetes or hypertension.
Both Wegovy and Ozempic contain the same active ingredient: semaglutide. Additionally, both medications are delivered once a week by injection. Wegovy, however, comes in higher doses than semaglutide. Wegovy is the first weight loss medication to receive approval since 2014 since it recently received approval in 2021.
Treatment for chronic weight management with Wegovy is the first drug-approved medication since 2014. Please review the following information about the medication before speaking with your healthcare provider about whether or not it is right for you.
As Wegovy contains higher doses of semaglutide, it can better cross the blood-brain barrier, increasing total weight loss. If prescribed Wegovy, your healthcare provider will start you on a low dosage and gradually increase it over 16-20 weeks.
Wegovy is starting at 0.25 mg per week. A maximum dose of 2.4 mg per week is available for this medication. Side effects can be reduced. Side effects can be reduced by gradually increasing the dose.
Wegovy is most commonly associated with gastrointestinal side effects. Among them are:
It is rare for serious side effects to occur, but they are still possible. You should seek emergency treatment if you experience any of the following symptoms:
GLP-1s have been researched for over 16 years and have consistently reduced body weight in obese patients with and without diabetes.
As part of its announcement of the approval, the drug approval cited the following results regarding the effectiveness of Wegovy for chronic weight management:
In addition to improving metabolic health and body weight, semaglutide has been shown to lower the risk of cardiovascular death, non-fatal myocardial infarctions, or non-fatal strokes in patients with type 2 diabetes at high risk.
Individuals with a family history of medullary thyroid cancer (a rare and primarily genetic cancer) are at risk of thyroid C-cell tumours. Patients suffering from multiple endocrine neoplasia syndrome type 2 (MEN 2) should avoid using it.
In people with type 2 diabetes, Ozempic can be taken with a diet and exercise program to control blood sugar levels. Adults with type 2 diabetes and heart and blood vessel disease can also benefit from it to reduce their risk of stroke, heart attack, or death.
Chronic weight management can also be achieved with it.
Ozempic and Wegovy contain the same active compound, but Ozempic has lower doses than Wegovy. Your provider will start you on a low dose of Ozempic: 0.25 mg weekly. You may increase your Ozempic dose every four weeks if your provider recommends it. Ozempic can take up to 1.0 mg per week if your doctor recommends it.
Ozempic may cause the same side effects as Wegovy since they contain the same active ingredient:
Wegovy can cause severe side effects and should be taken seriously. Seek medical assistance if you experience any of the following symptoms:
Ozempic, like Wegovy, has been shown to support weight loss combined with diet and exercise.
Type 2 diabetes can also be effectively managed with Ozempic.
Ozempic should not be used by individuals with medullary thyroid cancer and multiple endocrine neoplasia syndrome type 2 (MEN2). Any medications, supplements, or vitamins you're currently taking should be disclosed to your healthcare provider. GLP-1 or weight loss drugs should not be combined with Ozempic.
Overweight and obese individuals committed to implementing long-term behaviour modifications such as dietary changes, exercise, and stress management can benefit from Wegovy and Ozempic. Wegovy's higher doses may help some people lose weight, but what is best for one person may not work for another.
As a result, neither Wegovy nor Ozempic is intended to be "quick fixes" for weight loss.
To reap the benefits of either medication, you must follow your healthcare provider's recommendations to incorporate lifestyle modifications consistently.
Is Wegovy more effective than Ozempic?
Semaglutide is the active compound in Wegovy and Ozempic, which are glucagon-like peptide-1 receptor agonists (GLP-1s). However, Wegovy is available at slightly higher doses than Ozempic, which can assist in weight loss. It depends on your specific health factors; however, what works best for you?
Is Wegovy comparable to any other medications?
The active compound in Wegovy is semaglutide, a glucagon-like peptide-1s (GLP-1s). Others include liraglutide (Saxenda), dulaglutide (Trulicity), and semaglutide (Ozempic).
Is there a better alternative to Ozempic?
Ozempic is a GLP-1 medication that is used to treat type 2 diabetes. This drug is also approved for chronic weight management. Wegovy, liraglutide (Saxenda), and dulaglutide (Trulicity) are other GLP-1 medications. Your health history and goals will determine the best alternative for your circumstances.